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A B S T R A C T
The HIV epidemic continues to be a major global public health issue. Since 2012, there has been a paucity
of information from the Republic of the Congo on HIV incidence and prevalence rates, national HIV
programme effectiveness, highly active antiretroviral therapy (HAART) rollout, patient adherence to
treatment, operational and basic science research studies on HIV/AIDS, and donor funding and its impact
on the country. A review of the existing literature on HIV in the Republic of the Congo was conducted,
focused on prevalence trends, effectiveness of the current national HIV programme, HAART rollout,
patient adherence to antiretrovirals (ARVs), resistance to ARVs, the cost of treatment, and operational
issues affecting HIV/AIDS programmes in the country. In light of the ﬁndings, several important priority
areas for scaling-up HIV/AIDS services, programmatic and research activities in the Republic of the Congo
are highlighted.
Crown Copyright © 2018 Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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The HIV epidemic continues to be a major global public health
issue. In 2017, there were 25.7 million men, women, and children
living with HIV/AIDS in Sub-Saharan Africa, accounting for two-
thirds of the global total of new HIV infections (UNAIDS, 2018).
The Joint United Nations Programme on HIV/AIDS (UNAIDS) Fast-
Track strategy aims to increase the HIV response in low- and
middle-income countries to end the epidemic by 2030 (Sidibé
et al., 2016). This will require country HIV programmes to detect
and treat all people living with HIV/AIDS (PLWHA) with highly
active antiretroviral therapy (HAART), so that the HIV viral load
reduces to a level where the HIV-infected person is unlikely to
transmit HIV to others, thus curtailing the transmission cycle
(WHO, 2015). Current WHO ﬁgures estimate that in 2017 there
were 17 million PLWHA who were receiveing HAART worldwide
(UNAIDS, 2018) .
The Republic of the Congo (RoC) has a population of nearly ﬁve
million, and life-expectancy at birth was 63 years in 2016. The
Secrétariat Exécutif Permanent/Comité National de Lutte Contre le
SIDA (SEP/CNLS) is responsible for coordinating the National HIV
response. A notiﬁcation system for HIV/AIDS cases does not exist in
RoC, therefore there are no accurate and reliable epidemiological,
clinical, and management outcomes data on HIV/AIDS. Data on HIV
prevalence in RoC are scarce and come indirectly from small
individual studies. The point prevalence of HIV infection in Pointe-
Noire was 14% in 2000 and 5% in Brazzaville between 1996 and
2000. The HIV prevalence in sex workers was 34.3% in Brazzaville
and 64.1% in Pointe-Noire (UNAIDS and WHO, 2004). In 2012, an
HIV-related behavioural survey of sex workers, men who have sex
with men (MSM), and prisoners in four locations across the
country (Cuvette-Ouest, Plateaux, Pool, and Lékoumou), found HIV
prevalence of 3.2% in the general population aged 15–49 years,
which was slightly higher in urban (3.3%) than in rural areas (2.8%).
The HIV prevalence among MSM was 26.1% and among sex workers
was 7.5% (WHO Regional ofﬁce for Africa, 2006). The HIV
prevalence of 8.3% among prisoners was higher than in the
general population (WHO Regional ofﬁce for Africa, 2006).
Since 2012, there has been a paucity of information from RoC on
HIV incidence and prevalence rates, national HIV programme
effectiveness, HAART rollout, patient adherence to treatment,
operational and basic science research studies on HIV/AIDS, and
donor funding and its impact on the country. A review of the
existing literature on HIV in RoC was therefore conducted, focused
on the prevalence trends, effectiveness of the current national HIV
programme, HAART rollout, patient adherence to ARVs, resistance
to ARVs, the cost of treatment, and operational issues affecting
HIV/AIDS programmes in the country. Several important priority
areas for the public health response to HIV in RoC are discussed in
light of the study ﬁndings.
Methods
Reports and publications published in English and French were
identiﬁed through a search of the PubMed database covering the
period September 1, 1995–September 1, 2017 using the keywords
‘Congo’ or ‘Republic of Congo’ with the terms ‘HIV’ and ‘AIDS’ and
combinations with ‘incidence’; ‘prevalence’; ‘HAART’; ‘ARV’;
‘rollout’; ‘treatment’; ‘toxicity’; ‘side effects’; ‘adherence’; ‘HIVprogram’; ‘AIDS program’; ‘PLWHIV’; ‘HIV-infected’; ‘Sex workers’;
‘gender’; ‘donor’; ‘HIV research’; ‘AIDS research’; and ‘funding’.
Search results that were found to be relevant to HIV in RoC and
Africa were selected for this review. Other studies cited in articles
identiﬁed in the searches that were relevant to HIV in Africa and
RoC were also reviewed. Internal reports on HIV/AIDS published by
RoC nationally; and reports by external agencies such as the WHO;
UNAIDS; Unitaid; and the Global Fund to Fight AIDS; Tuberculosis
and Malaria (Global Fund) related to HIV/AIDS in Africa were also
reviewed .
Results
Eighty publications were identiﬁed through the search
(Figure 1). Fifty-nine articles and publications that were not
relevant to RoC were excluded. Furthermore, publications from the
Democratic Republic of the Congo (DRC) were excluded, as DRC is a
different country and appeared frequently in the search due to the
similarity of names. A further ﬁve articles that mentioned RoC but
were not relevant to HIV in RoC were also excluded. Thirteen
publications were selected for the ﬁnal analysis, of which eight
were PubMed articles, three were RoC national reports, and 10
were reports from global health agencies such as the WHO,
UNAIDS, UNITAID, and the Global Fund. This review of the
literature conﬁrmed the paucity of data on HIV in RoC. Of the
80 articles identiﬁed, there were only eight articles in the PubMed
database and three RoC government reports relevant to HIV and
HAART in RoC. The absence of an effective notiﬁcation, data
collection and reporting system for HIV/AIDS cases in RoC has led
to a paucity of accurate and reliable epidemiological, clinical, and
management outcomes data on HIV/AIDS.
Discussion
In light of the paucity of data available in the literature, the
discussion is focused on HIV prevalence trends, the effectiveness of
the current national HIV programme, HAART rollout, patient
adherence to ARVs, resistance to ARVs, the cost of treatment, and
operational issues affecting HIV/AIDS programmes in RoC. The
priority needs for further development of the national public
health response to HIV, improving the quality and quantity of the
cascade of HIV care, and taking forward current priorities for
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discussed.
Development of the national public health response to HIV
In March 2006, RoC committed to the Brazzaville Commitment
on scaling up towards universal access to HIV and AIDS prevention,
treatment, care, and support in Africa by 2010 (WHO Regional
ofﬁce for Africa, 2006). This was formulated by the Continental
Consultation on Scaling up towards Universal Access in Africa
convened by the African Union (which represents 53 African
Member States) with support from the WHO, UNAIDS, Economic
Commission for Africa (ECA), and the UK Department for
International Development (DFID) and with representatives from
governments, parliaments, civil society, PLWHA, faith-based
organizations, and the private sector from the 53 Member States
of the African Union. An ambitious initiative for reducing the HIV/
AIDS burden in RoC in 2008 recommended free healthcare for
PLWHA, including diagnostic tests, HAART treatment, and follow-
up (LNSP, 2012). In 2011, legislation called “Lutte contre le VIH et le
SIDA, et pour la protection des droits des personnes vivant avec le
VIH” was introduced to support healthcare for PLWHA to prevent
recurrence of the frequent shortages of ARVs that occurred during
the establishment of the Congolese Access to Antiretroviral
Initiative between 2004 and late 2006.
From 2004 to 2005, a fee of between 6.68 USD and 66.80 USD
was charged to the patient for HAART medicines, the exact amount
depending on the patient’s socio-economic status (ONU, 2011).
This was not affordable to many patients. Thus, as of 2006, through
the Congolese Agency for Essential and Generic Medicine
(COMEG), the government of RoC established a national pro-
gramme of free access to ARVs, although patients had to pay
laboratory costs for monitoring CD4+ T-cell counts and viral load
measurements. This led to most patients not presenting for follow-
up. Thus, accurate data on the effectiveness of ARVs among the
PLWHA and the degree of development of HIV resistance to ARVs
are not available. The Global Fund lent its support to RoC in 2012,Figure 2. HIV testing and treatment ceensuring that HIV testing and HAART were provided free of charge
to PLWHA across public health facilities throughout the country.
Figure 2 shows the geographical distribution of HIV diagnostic and
treatment centres in RoC. By the end of 2014, the Centre de
Traitement Ambulatoire au Congo was providing care for 6430
PLWHA, including 5677 (88.3%) on HAART.
Cascade of care and management issues
Adherence
Adherence by patients to HAART is an important issue for HIV/
AIDS services across Africa (Bekker et al., 2014). HIV/AIDS
treatment requires several doses of ARVs every day, thus
necessitating a reliable drug supply. Side-effects of ARVs can also
prompt PLWHA to suspend or discontinue treatment (Bekker et al.,
2014). An 18-month retrospective study conducted in Brazzaville
of 157 patients on HAART for at least 12 months, showed that apart
from the effectiveness of ARVs and despite observed therapy in 84%
cases, 10.8% took their ARVs irregularly and 5.2% stopped
altogether (Dokekias et al., 2008). A study of adherence and
patient compliance conducted in RoC in 2009 involved a survey of
214 patients (mean age 42 years and only six children) at an
outpatient care and treatment centre in Brazzaville, Congo (Faure
et al., 2011), in which it was found that 92.5% of patients were
receiving ﬁrst-line HAART regimens and adherence rates achieved
were between 55% and 87%. In a study that looked at causes of
death in HIV-positive patients receiving ARVs at the French Red
Cross Outpatient Treatment Centre at Pointe-Noire, RoC, one of
several factors determined was non-adherence to treatment
(Lucaccioni et al., 2013). Further operational research studies are
required to deﬁne the main factors impeding adherence in order to
inform on appropriate measures to improve adherence, such as
public education or additional regular follow-up.
Optimizing and monitoring treatment
Monitoring of CD4+ cell counts and HIV viral load within RoC
HIV services is extremely limited due to non-functioningntres in the Republic of the Congo.
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causing substantial interruptions in the cascade of care. Due to the
limited availability and choice of ARVs in RoC, it is difﬁcult to tailor
ARV therapy to the speciﬁc needs of the patient when they develop
side effects or become intolerant. Furthermore, since genotyping of
HIV isolates is not possible in RoC, the optimal choice of ARVs is
also restricted (Beaulière et al., 2010). It is even more difﬁcult to
initiate a second- or third-line treatment regimen in the case of
therapeutic failure due to the development of resistance to ARVs.
Resistance to ARVs
The emergence and transmission of HIV strains resistant to
ARVs is now an important public health problem in RoC. In a study
conducted in ARV-naïve HIV-infected patients reported in 2012,
Pircher et al. (Pircher et al., 2012a) showed genetic diversity of HIV-
1 and the presence of mutations conferring antiretroviral drug
resistance in 50 drug-naïve infected persons in RoC. The most
prevalent subtypes were G with 10 isolates and D with 11 isolates.
Previous reports have shown the high genetic diversity in the
distribution of HIV-1 subtypes in RoC. Subtypes A, G, and D
predominate, but approximately 20–27% of strains circulating in
the country are recombinants (Ekat, 2015; Church et al., 2015a) and
6.3% of strains remain unclassiﬁed. Pircher et al. concluded that the
resistance to ARVs is the major cause of treatment failure (Pircher
et al., 2012b).
The administration of poor quality ARVs in the country may also
increase the risk of virus mutations conferring resistance to drugs
(Camara et al., 2015). To prevent virological failure and the
emergence of drug resistance mutations, the rigorous pharmaco-
logical monitoring of generic ARVs that are not pre-qualiﬁed by the
WHO but that are marketed in Africa, must be a priority for health
authorities (Camara et al., 2015).
In order to reduce the risk of the development of ARV
resistance, appropriate measures should be taken to educate
patients, simplify dosing, and enhance adherence monitoring. For
example, a clear and adapted case-management model for the
cascade of care from HIV counselling to healthcare could be
applied. Operational research ascertaining the reasons for poor
adherence should be at the front line for improving patient
adherence, and patients who are at risk of becoming lost to follow-
up should be identiﬁed proactively (Thompson et al., 2012; Beima-
Soﬁe et al., 2017).
Mother-to-child HIV transmission
A study conducted in 44 selected antenatal clinics (ANCs) in 12
departments in RoC (ﬁve urban and seven rural) assessed 2979
pregnant women attending these facilities (Niama et al., 2017). The
overall HIV infection rate was estimated to be 3.6%. This study
indicated that more investment was required to emphasize
prevention strategies to prevent mother-to-child and horizontal
transmission of HIV. Maternal and child mortality and morbidity
associated with HIV has been attributed to late HIV screening, the
absence or delayed initiation of ARV therapy during pregnancy, and
inadequate treatment for those with a detectable viral load in late
pregnancy (Vogler, 2014) . No data are available to assess the
impact of this lack of optimization on maternal and child
healthcare. The non-disclosure of the mother’s HIV status to the
father of the child, common in Africa including RoC, is associated
with less optimal prevention of mother-to-child transmission, but
has no impact on mother-to-child HIV transmission (Madiba,
2013).
Therapeutic failure among newly diagnosed mothers in RoC has
been attributed to resistant HIV strains (Bruzzone et al., 2015). The
study in Pointe-Noire analyzed 95 plasma samples from HIV-1-
positive treatment-naïve pregnant women collected over a periodof 18 months between 2005 and 2008 . Major mutations to
nucleoside reverse transcriptase inhibitors, non-nucleoside re-
verse transcriptase inhibitors, and protease inhibitors were
detected in 4/68 (5.9%), 3/68 (4.4%), and 2/68 (2.9%) of the patient
samples, respectively . The extremely high genetic variability of
viruses in RoC is an additional challenge, and justiﬁes systematic
monitoring of the response to treatment (Bruzzone et al., 2015);
unfortunately this is not the case.
Co-trimoxazole prophylaxis
In Brazzaville, in accordance with WHO HIV treatment guide-
lines, co-trimoxazole prophylaxis (CTXp) for HIV-infected infants
(from the age of 4 to 6 weeks) is administered irrespective of
disease stage, CD4 cell count, or use of HAART until the age of 14
years (Church et al., 2015b). CTXp prevents bacterial infections and
Pneumocystis jirovecii pneumonia in adults and children with HIV
infection (Church et al., 2015b). CTXp also reduces anaemia and
improves growth in children with HIV, possibly by reducing
inﬂammation. Studies are required to ascertain the cost-effective-
ness of CTXp in adolescents, particularly around reductions in
morbidity and mortality, and improvements in growth, especially
for children with HIV.
External funding for the HIV/AIDS programme in the Republic of the
Congo
For the past decade, the Global Fund has provided substantial
funding to RoC for HIV/AIDS, TB, and malaria services, amounting
to an estimated 51 billion CFA francs (68 305 349 GBP). For the
years 2014–2015, the Global Fund contributed a total of 16 156 313
Euros (14195 548 GBP) to RoC (Global Fund, 2015), as follows: 6
233 128 Euros to the Secrétariat Exécutif du Conseil Nationale de
Lutte Contre le SIDA (Executive Secretariat for the National HIV/
AIDS Council), 7 093 150 Euros to the French Red Cross, and
2 830 035 Euros to the administrative and ﬁnancial technical
coordination of the Ministry of Public Health. This funding was part
of the second phase of the project “Support to strengthen the
national response to HIV among at-risk populations in the Congo”,
which tackles socio-economic factors associated with HIV such
stigma and marginalization. For the period 2017–2019, the Global
Fund will contribute a total of 27 912 895 Euros, of which
11539 955 Euros will be for HIV/AIDS activities. The International
Monetary Fund funding for HIV/AIDS, malaria, and TB requires
their contributions to be matched by 20% of the total by the host
country. Currently, RoC is eligible to apply to the International
Monetary Fund allocations for the years 2018–2020. Donor funding
for the HIV response in low- and middle-income countries
declined by almost 13% between 2014 and 2015 (UNAIDS and
The Henry J Kaiser Family Foundation, 2016). Access to ARVs has no
doubt dramatically reduced mortality and morbidity (Grace, 2016)
and transformed the lives of PLWHA, returning them to a near-
normal lifespan (Samji et al., 2013).
ARV supply chain and quality of drugs
The drug supply and rollout chain for free ARVs in RoC has
suffered from many interruptions and issues of supply, quality, and
expiry dates, and this has dogged the management of PLWHA
(Agence d’information d’Afrique Centrale, 2013). Previously
COMEG was responsible for the procurement of ARVs from foreign
distributors, and the storage and distribution of these ARVs at the
national level . Regarding the reagents for HIV testing and follow-
up CD4+ cell counts and HIV viral load measurements, advanced
payment by local structures was acceptable, with refunds from the
Table 1
Priorities for scaling up HIV/AIDS programmatic activities in the Republic of the Congoa.
1. Observing respect for human rights; overcoming stigma and discrimination; advancing equity and gender-centred approaches; putting people (PLWHA, civil society
groups, community) at the centre of the HIV and AIDS response.
2. Fostering and ensuring accountability (political, ﬁnancial, moral, and programmatic) at every level of the response. This includes honest, transparent, and accountable
use of donor funding.
3. Taking forward an unwavering commitment by the government of RoC to massively scale up and deliver a ‘cost-free’ comprehensive package of services for prevention,
treatment, care, and support for HIV and AIDS.
4. Ensuring a regular and continuous supply of HIV diagnostics, ARVs, and laboratory reagents for CD4+ T-cell counts, HIV viral load measurement, and genotyping for
resistance.
5. Establishing links between HIV services across all health sectors, including maternal and child health programmes.
6. Integrating TB and HIV care.
7. Increasing human resources by training and empowering all grades of healthcare workers, laboratory personnel, and community care staff.
8. Establishing effective collaborative regional and pan-African networks to accelerate priority research and training on HIV linked with TB, malaria, respiratory tract
infections, and other co-morbidities.
9. Establishing an effective data management system with accurate reporting, record-keeping, and reporting to the WHO, allowing for more accurate data on prevalence,
incidence, and trends.
10. Conducting priority operational, epidemiological, translational, clinical, and basic science research to ﬁll data gaps and to inform patient adherence, ARV resistance,
tailored ARV therapy, and surveillance.
11. Committing local governmental funds, increasing domestic resources, and weaning off dependency on external donor aid.
PLWHA, people living with HIV/AIDS; RoC, Republic of the Congo; ARVs, antiretrovirals; WHO, World Health Organization.
a Modiﬁed and adapted from the WHO Regional Ofﬁce for Africa report (WHO Regional ofﬁce for Africa, 2006).
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funded by both the government of RoC and the Global Fund.
ARV procurement procedures are complex, particularly because
of the multiplicity of donors involved in the ﬁeld of antiretroviral
drugs, with the procurement procedures being speciﬁc to each
donor. The orders are not centralized and this often results in a
breakdown of the drug supply chain (Libaudière et al., 2006),
which is not well established in RoC. The Global Fund made two
changes to allocations to in 2013 (Anon, 2013): 2013): 1) funds
allocated by the Global Fund could be used for the direct purchase
of ARVs, and (2) ARVs were to be channelled through local NGOs for
distribution to the beneﬁciaries. The health services in RoC have
continued to face disruptions in drug supply for ﬁrst- and second-
line ARVs. As an example, in 2015 there was an acute shortage of
Atripla, a combination pill consisting of efavirenz, emtricitabine,
and tenofovir disoproxil fumarate. This error in supply chain
disrupted the HAART treatment regimens of numerous patients,
with a possible impact on the development of HIV viral resistance.
Approximately 12% of the 18 000 patients who are on ARVs in RoC
are taking Atripla. During shortages, some patients on Atripla are
switched to other ARV regimens that are not optimal (Agence
d’information d’Afrique Centrale, 2014). The latest drug supply
shortage was recorded in March 2017, when there were an
estimated 23 000 adults and over 1500 children on HAART. The
HIV/AIDS Sustainability Index and Dashboard (Anon, 2016) is a tool
used by the US donor agency PEPFAR (President’s Emergency Plan
for AIDS Relief) to determine a country’s sustainability landscape
for HIV/AIDS. This should be used to monitor funding and make
available additional funds from the government to sustain the
rising trajectory of rollout and access to antiretroviral therapy.
Priorities for HIV/AIDS programme strengthening in the Republic of
the Congo
Table 1 lists priorities for the scale-up of HIV/AIDS program-
matic activities in RoC (modiﬁed and adapted from a WHO report
(WHO Regional ofﬁce for Africa, 2006)). Observing respect for
human rights, ﬁghting stigma and discrimination, advancing
equity and gender-centred approaches, and putting people
(PLWHA, civil society groups, community) at the centre of the
HIV and AIDS response is critical to its success. Taking forward an
unwavering commitment by the government of RoC to massively
scale up and deliver a ‘cost-free’ comprehensive package of
services for prevention, treatment, care, and support for HIV and
AIDS is required to get everyone diagnosed and treated.Establishing links between HIV services across all health sectors,
including maternal and child health programmes, and integrating
TB and HIV care will provide a holistic approach to the
management of patients (Linguissi et al., 2017).
The lack of data on HIV in RoC emphasized by this study makes
an important case for establishing an effective data management
system with accurate reporting, record-keeping, and reporting to
the WHO, allowing for more accurate data on prevalence,
incidence, and trends over time. The paucity of research
publications from RoC makes the performance of operational
and basic science research a priority. This is required to ﬁll existing
data gaps and provide an evidence base on patient adherence, ARV
resistance, tailored ARV therapy, monitoring, follow-up, and
surveillance. This will require increased political and ﬁnancial
commitments from the government of RoC and increased external
donor funding.
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